2 funding - 6,304€

data available since 2019

2020

  1. Evaluation of the anti-CD160 antibodies in in vivo models.

    euro 5,000.00

2019

  1. Evaluation of anti-CD160 antibodies in "in vivo" models.

    euro 1,304.35